Recent progress in the synergistic combination of nanoparticle‐mediated hyperthermia and immunotherapy for treatment of cancer
ZR Stephen, M Zhang - Advanced healthcare materials, 2021 - Wiley Online Library
Immunotherapy has demonstrated great clinical success in certain cancers, driven primarily
by immune checkpoint blockade and adoptive cell therapies. Immunotherapy can elicit …
by immune checkpoint blockade and adoptive cell therapies. Immunotherapy can elicit …
Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung …
Y Shi, Y Lei, L Liu, S Zhang, W Wang, J Zhao… - Cancer …, 2021 - Wiley Online Library
Objectives This study aimed to explore the novel biomarkers for immune checkpoint inhibitor
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling …
(ICI) responses in non‐small cell lung cancer (NSCLC) by integrating genomic profiling …
[HTML][HTML] Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up …
S Lu, J Wang, Y Cheng, T Mok, J Chang, L Zhang… - Lung Cancer, 2021 - Elsevier
Abstract Background In the phase 3 CheckMate 078 study, nivolumab showed significant
overall survival (OS) benefit and superior tolerability versus docetaxel in a predominantly …
overall survival (OS) benefit and superior tolerability versus docetaxel in a predominantly …
[HTML][HTML] NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer
Y Cheng, Q Zhou, B Han, Y Fan, L Shan, J Chang… - Lung Cancer, 2023 - Elsevier
Objectives The phase 3 NEPTUNE study (NCT02542293) evaluated first-line durvalumab
plus tremelimumab (DT) versus chemotherapy for metastatic NSCLC. Prespecified …
plus tremelimumab (DT) versus chemotherapy for metastatic NSCLC. Prespecified …
[HTML][HTML] Accurate segmentation for different types of lung nodules on CT images using improved U-Net convolutional network
X Zhang, X Liu, B Zhang, J Dong, S Zhao, S Li - Medicine, 2021 - journals.lww.com
Since lung nodules on computed tomography images can have different shapes, contours,
textures or locations and may be attached to neighboring blood vessels or pleural surfaces …
textures or locations and may be attached to neighboring blood vessels or pleural surfaces …
A novel deep learning approach to extract Chinese clinical entities for lung cancer screening and staging
Background Computed tomography (CT) reports record a large volume of valuable
information about patients' conditions and the interpretations of radiology images from …
information about patients' conditions and the interpretations of radiology images from …
[HTML][HTML] Successful treatment of EGFR T790M-mutant non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: a case report and …
L Wu, W Zhong, A Li, Z Qiu, R Xie, H Shi… - Annals of Translational …, 2021 - ncbi.nlm.nih.gov
Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs)
have revolutionized the standard treatment for EGFR T790M-positive non-small cell lung …
have revolutionized the standard treatment for EGFR T790M-positive non-small cell lung …
A qualitative research exploring the experiences of patients receiving immune checkpoint inhibitors for advanced lung cancer
Y Hou, Y Hou, J Li, L Yu, L Yan - Supportive Care in Cancer, 2023 - Springer
Purposes In patients with advanced lung cancer, immune checkpoint inhibitors (ICIs)
dramatically extended survival. We aimed to investigate the experiences of patients with …
dramatically extended survival. We aimed to investigate the experiences of patients with …
Dysregulation of Pseudogenes/lncRNA‐Hsa‐miR‐1‐3p‐PAICS Pathway Promotes the Development of NSCLC
Y Song, Z Wang, L He, F Sun, B Zhang… - Journal of …, 2022 - Wiley Online Library
Objective. Non‐small cell lung cancer (NSCLC) explains about 80 percent of whole lung
cancers, and its 5‐year survival rate is impoverished, as when people are first diagnosed …
cancers, and its 5‐year survival rate is impoverished, as when people are first diagnosed …
Thyroid dysfunction (TD) induced by PD-1/PD-L1 inhibitors in advanced lung cancer
Y Wang, X Yang, J Ma, S Chen, P Gong, P Dai - Heliyon, 2024 - cell.com
Abstract Background Thyroid Dysfunction (TD) is a common immune-related adverse events
(irAEs) in the treatment of advanced lung cancer with programmed cell death protein 1 (PD …
(irAEs) in the treatment of advanced lung cancer with programmed cell death protein 1 (PD …